Program
HRS-5346
A development code. Also written as “MK-7262” and “HRS-5346 tablets”.
In Jiangsu HengRui Medicine's pipeline, Lp(a)
. Its studies are led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 42 open or running | phase 2since Feb 4, 2025 | May 28, 2024 | Feb 2027phase 2 · NCT07767513 |
| Merck | 21 open or running | phase 2since May 22, 2026 | May 22, 2026 | Oct 12, 2027phase 2 · NCT07614984 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-5346
, phase 2, as of Jul 31, 2026 (source). - Named in Merck’s own pipeline as
MK-7262
, phase 2, as of Nov 2, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseMerck licensed it from Hengrui, for everywhere outside Greater China.Announced Mar 25, 2025 · Source: Merck, Mar 25, 2025
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 28, 2024First study: phase 1 study in Lipoprotein Disorder DiseaseNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06441227 · 71 enrolled · China
- Feb 4, 2025Phase 2 study in Treatment of Lipoprotein DisorderJiangsu HengRui Medicine · NCT06816264 · 120 enrolled · China
- May 22, 2026Merck's first study: phase 2 study in Lipoprotein(a)New to MerckMerck · NCT07614984 · 750 planned · United States, Canada, Colombia and more
- May 27, 2026Phase 1 study in HealthyMerck · NCT07619443 · 30 enrolled · United States
- Aug 4, 2026Phase 1 study in Lipoprotein DisorderJiangsu HengRui Medicine · NCT07752069 · 50 planned · China
- Aug 12, 2026Phase 2 study in Lipoprotein DisorderJiangsu HengRui Medicine · NCT07767513 · 60 planned · China
Ahead
- Feb 2027Primary completion: phase 2 study in Lipoprotein DisorderJiangsu HengRui Medicine · NCT07767513
- Oct 12, 2027Primary completion: phase 2 study in Lipoprotein(a)Merck · NCT07614984
TargetBeta
“Lp(a)”the company's pipeline, read by Claude · source
Other programs on LPA
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07767513Lipoprotein Disorder · China | 2 | Recruiting | Jiangsu HengRui Medicine | Feb 2027 | 60 |
| NCT07752069Lipoprotein Disorder · China | 1 | Not yet recruiting | Jiangsu HengRui Medicine | Sep 2026 | 50 |
| NCT07619443Healthy · United States | 1 | Completed | Merck | Sep 5, 2026 | 30 |
| NCT07614984Lipoprotein(a) · United States, Canada, Colombia and more | 2 | Recruiting | Merck | Oct 12, 2027 | 750 |
| NCT06816264Treatment of Lipoprotein Disorder · China | 2 | Completed | Jiangsu HengRui Medicine | Sep 29, 2025 | 120 |
| NCT06441227Lipoprotein Disorder Disease · China | 1 | Completed | Jiangsu HengRui Medicine | Jan 9, 2025 | 71 |
How it is read
Names in the registry
- “HRS-5346”, 5 entries
- “MK-7262”, 2 entries
- “HRS-5346 tablets”, 1 entry
Codes read as this program: HRS5346, MK7262.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.